重新定义结肠直肠癌的治疗方法:准分子通路并克服抵抗力
Simona Gabriela Duta-Ion1, Ioana Ruxandra Juganaru1, Iulian Andrei Hotinceanu1
1Department of Medical Genetics, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
本综述探讨了结直肠癌 (CRC) 的分子途径,重点关注推动瘤生长的遗传和表观遗传变化. 了解这些机制是个性化治疗和克服疗法耐药性的关键.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 结肠直肠癌 (CRC) 的发展是由复杂的遗传和表观遗传改变驱动的.
- 关键的分子通路极大地影响瘤的生长,进展和治疗反应.
研究的目的:
- 审查与结直肠癌 (CRC) 有关的主要分子途径.
- 讨论基因突变和表观遗传修饰在CRC瘤发生中的作用.
- 在CRC治疗中探索向疗法和抵抗机制.
主要方法:
- 关于CRC的主要分子通路的文献综述.
- 对关键基因突变 (APC,KRAS,NRAS,BRAF,TP53) 和它们相关的信号通路 (Wnt,EGFR,PI3K/AKT) 的分析.
- 对染色体不稳定性 (CIN),微卫星不稳定性 (MSI) 和CpG岛甲基化表型 (CIMP) 的检查.
主要成果:
- 遗传和表观遗传改变激活了驱动CRC的关键信号通路.
- 关键基因的突变有助于瘤发生,并影响向治疗的疗效.
- 治疗耐药性的机制,包括旁路突变,构成重大挑战.
结论:
- 分子分析对于指导CRC个性化向疗法至关重要.
- 新型组合治疗提供了提高疗效和克服耐药性的策略.
- 对分子机制的深入理解对于改善CRC患者预后至关重要.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Stabilize Microtubules
Tumor Immunotherapy
